Objective: We aimed to investigate the possible association between SCN2A mutations and earlyonset epileptic encephalopathies (EOEEs).
respectively, are highly expressed in the human brain, 13 and mutations can cause epilepsies and psychiatric disorders. [14] [15] [16] [17] Most SCN2A mutations cause benign phenotypes such as benign familial neonatal-infantile seizures (BFNIS), 18 and are usually inherited from an affected parent. In contrast, several de novo SCN2A mutations have been reported to cause more severe phenotypes, 14, [19] [20] [21] [22] suggesting a possible involvement in severe epileptic encephalopathies.
To elucidate the genetic basis of OS, we performed exome sequencing and found a de novo SCN2A mutation. Subsequently, we screened patients with EOEE for SCN2A mutations, and found that de novo SCN2A mutations contributed to the development of severe epileptic encephalopathies.
METHODS Patients. A total of 328 patients with EOEE (67 patients with OS, 150 with WS, and 111 with unclassified EOEE) were analyzed for SCN2A mutations. The 67 patients with OS consisted of 44 Japanese and 23 non-Japanese (from other countries). The diagnosis was made based on clinical features and characteristic patterns on EEG. In 257 patients, mutations in STXBP1 and KCNQ2 had been excluded by high resolution melt (HRM) analysis in advance. Mutation analysis was performed by HRM analysis or direct sequencing, and 41 of the 328 patients (32 with OS, 4 with WS, and 5 with unclassified EOEEs) were also analyzed by whole exome sequencing (WES). We obtained detailed clinical data from all patients with SCN2A mutations, including brain MRI/CT and EEG findings.
Mutation screening. Genomic DNA was obtained from peripheral blood leukocytes by standard methods. DNA for mutation screening was amplified using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare Japan, Tokyo, Japan). Mutation screening of exons 2 to 27 (including exon 6A) covering the SCN2A coding regions (transcript variant 1, NM_021007.2) and exon 6N of transcript variant 3 (NM_001040143.1) was performed by HRM analysis or by direct sequencing of part of exon 27. The DNA of patient 10 from nails and hairs was isolated using ISO-HAIR (Nippon Gene, Tokyo, Japan), and DNA in saliva was isolated using Oragene (DNA Genotek, Kanata, Canada). Real-time PCR and subsequent HRM analysis were performed using a Light Cycler 480 (Roche Diagnostics, Otsu, Japan). Samples showing an aberrant melting curve in the HRM analysis were sequenced. PCR primers and conditions are shown in table e-1 on the Neurology ® Web site at www.neurology.org. All novel mutations were verified using original genomic DNA, and searched for in the variant database of our 212 in-house control exomes.
Whole exome sequencing. DNAs were captured using the Sure-Select XT Human All Exon v4 Kit (Agilent Technologies, Santa Clara, CA) and sequenced with 4 samples per lane on an Illumina HiSeq 2000 (Illumina, San Diego, CA) with 101-base pair paired-end reads. Image analysis and base calling were performed by sequence control software with real-time analysis and CASAVA software v1.8 (Illumina). Reads were aligned to GRCh37 with Novoalign (Novocraft Technologies, Selangor, Malaysia), and duplicate reads were marked using Picard (http://picard.sourceforge.net/index.shtml) and excluded from downstream analysis. Local realignments around indels and base quality score recalibrations were performed using the Genome Analysis Toolkit (GATK). 23 Single-nucleotide variants and small indels were identified using the GATK, and were annotated using ANNOVAR. 24 All mutations detected by WES were confirmed by Sanger sequencing.
Parentage testing. For the family showing de novo mutations, parentage was confirmed by microsatellite analysis using ABI Prism Linkage Mapping Set version 2.5, MD10 (Life Technologies, Carlsbad, CA). We chose 12 probes for screening (D6S422, D7S493, D8S285, D9S161, D10S208, D11S987, D12S345, D16S503, D17S921, D18S53, D19S220, and D20S196). Appropriate biological parentage was confirmed if 3 or more informative markers were compatible and other markers showed no discrepancy.
Standard protocol approvals, registrations, and patient consents. The experimental protocols were approved by the Institutional Review Boards for Ethical Issues of Yokohama City University School of Medicine and Yamagata University Faculty of Medicine. Informed consent was obtained from the families of all patients.
RESULTS
Identification of SCN2A mutations. We previously performed WES of 12 patients with OS, including patient 142 of the current study. 7, 25 To systematically find de novo mutations, we additionally analyzed the parents of patient 142 by WES. We found 2 de novo nonsynonymous mutations in patient 142: c.4868C.A (p.T1623N) in SCN2A and c.538A.T (p.I180F) in FHOD1. Because de novo SCN2A mutations have been reported to cause intractable epilepsy, 19, 21 the SCN2A mutation was highly likely to have caused the OS. In fact, we found a total of 14 mutations in 15 patients: 9 of 67 OS cases (13.4%), 1 of 150 WS cases (0.67%), and 5 of 111 with unclassified EOEEs (4.5%) (table 1). One mutation (c.638T.A) occurred recurrently in 2 patients, and the mutation was confirmed as a de novo event in 1 of the 2 patients. All other mutations except for 2 (c.2995G.A and c.4886G.T; parents were unavailable) occurred de novo. Interestingly, a de novo mosaic mutation (c.3976G.C) was detected by WES in patient 10. The mutant allele frequency was 18% (37/205 alleles) based on read counts of WES. We confirmed mosaicism in hair, nail, and saliva DNA samples (figure e-1). One mutation (c.634A.G [p.N212D]) was found in the transcript variant 3, which is a neonatal isoform. All of the 15 mutations are missense changes that have not been previously reported. They cannot be found in the 6,500 exomes sequenced by the National Heart, Lung, and Blood Institute exome project or among our 212 in-house control exomes. Sorting Intolerant From Tolerant (SIFT), Polyphen2, and Mutation Taster predicted that all mutations would be highly damaging to the structure of Na v 1.2 (table e-2). All 9 mutations in patients with OS were located in linker regions between transmembrane segments (figure 1). Six of these mutations were located in a linker between S4 and S5, 2 were located between S3 and S4, and one near the end of S6. One mutation in a patient with WS was located in a positively charged segment (S4) of domain II. Other mutations found in patients with unclassified EOEE were located in S4 of domain IV (1 mutation), a linker between S3 and S4 of domain I (1 mutation), and in S2 and S5 of domain I (2 mutations).
Clinical features of SCN2A mutations. The clinical information and EEG and MRI findings of patients with SCN2A mutations are summarized in table 1 and figure 2. Case reports (in appendix e-1) and further EEG (in figure e-2) and MRI (in figure e-3) findings are shown in supplemental data. There were 9 patients with OS (6 Japanese, 1 Canadian, 1 Mexican, and 1 Israeli), 1 with WS (Japanese), and 5 with unclassified EOEE (4 Japanese and 1 Slovenian). The ratio of females to males was 9:6. The mean age at onset was 45.3 days after birth (5.7 days in patients with OS; 65 days in unclassified EOEE; 10 months in a patient with WS). The initial epileptic attacks were tonic seizures in 8 patients, spasms in 3 patients, clonic seizures in 3 patients, and generalized tonic-clonic seizures in 1 patient. Three patients (patients 99, 254, and 305) had dystonia, and patient 99 also had chorea and ballismus. EEG at epilepsy onset showed suppression-burst pattern in 9 patients and focal or multifocal spikes in 6 patients. Seven of 15 patients with SCN2A mutations received adrenocorticotropic hormone therapy, leading to a transient reduction of seizures followed by recurrence. Epileptic seizures disappeared and EEG findings improved in 2 patients with WS and unclassified EOEE after administration of lamotrigine (patients 99 and 305), and in 1 patient with OS after combination therapy with zonisamide, levetiracetam, phenytoin, and vigabatrin (patient 146). Twelve of the 15 patients could not be controlled with antiepileptic drugs. All 15 patients had severe developmental delay, and 1 patient with unclassified EOEE (patient 185) died at the age of 5 years. Brain MRI showed cerebral atrophy in 10 patients, thin corpus callosum in 7 patients, delayed myelination in 5 patients, and cerebellar atrophy in 3 patients. MRI was normal in 2 patients in the early infantile period (1 and 2 months of age). Of the 9 patients with OS, 6 showed spasms, and all patients showed suppression-burst pattern on EEG at epilepsy onset. Seven patients with OS developed WS, and 1 case (patient 230) was suspected to do so because of spasms and developmental delay; however, no EEG was done to verify this. DISCUSSION We identified 14 novel SCN2A mutations in 15 patients with EOEE. Two of the mutations could not be confirmed as de novo, but all mutations showed high scores for predicted negative effects on protein function, and were not found in our in-house control exome data. Of note, 9 of the 15 patients were diagnosed with OS, and all patients showed severe developmental delay. Previously, SCN2A mutations have been reported in a wide spectrum of disorders, including autism, severe nonsyndromic sporadic intellectual disability, benign seizure syndromes such as BFNIS, benign familial infantile seizure, and generalized epilepsy with febrile seizures plus, and severe epileptic disorders such as DS, infantile spasms, and AERRPS (acute encephalitis with refractory, repetitive partial seizures). [18] [19] [20] [21] [22] [26] [27] [28] [29] [30] [31] [32] [33] Most of the disorders caused by SCN1A mutations involve DS or generalized epilepsy with febrile seizures plus, and onset of DS is usually in the infantile period. 17 By contrast, the onset of OS is neonatal and that of BFNIS is neonatal or early infantile. The phenotypic differences between SCN2A and SCN1A mutations might be explained by the different expression patterns of the channels. Na v 1.2 (SCN2A) and Na v 1.6 (SCN8A) are the major sodium channel a subunits in excitatory neurons. Na v 1.2 channels are expressed early in development and Na v 1.6 channels gradually replace Na v 1.2 channels in a population of neurons during maturation. 31 Na v 1.2 is expressed predominantly at terminals, unmyelinated axons, and in proximal axon initial segments, where action potentials are initiated, whereas Na v 1.1 (SCN1A) is expressed predominantly in neurons releasing g-aminobutyric acid, and is localized to the soma and proximal processes of the neuron. 13, 14, 34, 35 Therefore, SCN1A mutations may mainly lead to a reduction of sodium-channel activity in inhibitory neurons, increasing net excitability. However, SCN2A mutations likely also affect excitatory neurons and proximal axon initial segments especially during the early developmental period. Therefore, the effect of SCN2A mutations on the net excitability of neurons may result in earlier onset of epileptic disorders. Investigation of the genotype-phenotype correlation of SCN2A mutations may contribute to our understanding of the pathophysiologic mechanisms of seizures caused by SCN2A mutations. SCN2A mutations causing BFNIS tend to be located in transmembrane regions (7/11 mutations), whereas mutations causing intractable epilepsies were located outside transmembrane domains, such as upstream of domain I or between 2 domains. 18, 19, 21, 26, 28 In this study, all 9 mutations causing OS were found in linkers between transmembrane regions of Na v 1.2, especially between S4 and S5 of domain III. The S4-S5 linker of domain III interacts with the linker of domains III and IV, which is critical for fast inactivation of the sodium channel, 12, 36 suggesting that alteration of this linker region may specifically affect the function of Na v 1.2. Similarly, the mutation causing WS was located in a positively charged segment (S4) of domain II, where no mutations have been previously reported. Interestingly, patient 10 showing OS had a low-level mosaicism of the p.V1326L mutation, which was confirmed in DNA samples from blood leukocytes, hair follicle, nail, and saliva. There are no previous reports of mosaicism for SCN2A mutations, but one case of mosaic 2q24 duplication including SCN2A and SCN3A has been reported. 37 The mosaic duplication was detected in 40% to 51% of blood cells, and the phenotype partially overlapped with both DS and BFNIS. 37 In cases of SCN1A mutations in familial DS, mosaic carriers with approximately 25% mutated alleles had experienced simple febrile seizure, whereas a carrier with approximately 12.5% mutated alleles was asymptomatic. 38 Patient 10 showed a very severe OS phenotype despite the low rate of mosaicism (18%). However, we did not determine whether the same mosaic rate was maintained in brain tissue. The location of the p.V1326L mutation in a linker of S4 and S5 of domain III might support the hypothesis that alteration of linker regions, especially between S4 and S5 of domain III, uniquely affects the function of Na v 1.2 in association with OS. Patient 252 with OS had a de novo mutation in exon 6N, which is a neonatal isoform (transcript of variant 3). SCN1A, SCN2A, SCN3A, and SCN8A are subject to alternative splicing of exon 6N and 6A. In the developing mouse brain, Scn2a shows higher or equal amounts of the 6N isoform compared with the 6A isoform at birth, but 6N is gradually replaced by 6A during postnatal development. 39 The channels of the neonatal isoform are less excitable than the adult isoform. 40 In patient 252, the age of seizure onset was 14 days, which was relatively late compared with the other cases of OS. The expression of abnormal neonatal isoforms would be expected to gradually decrease, leading to an alleviation of neuronal hyperexcitability. In contrast, his symptoms, such as the transition to WS, development delay, and cerebral atrophy, worsened with increasing age. Further studies are required to clarify how mutations of the 6N isoform are involved in pathogenesis of EOEE.
To date, many disease-causing genes contributing to EOEE phenotypes have been identified, including ARX, CDKL5, STXBP1, SPTAN1, KCNQ2, SCN1A, and SCN2A. [5] [6] [7] [8] [9] [10] [11] 17, 20, 21 In addition, mutations in one gene can cause a wide phenotypic spectrum as revealed by previous reports and the results of this study. 6, 7, 25 Therefore, rapid genetic diagnosis of EOEEs by screening for all known disease-causing genes with Sanger sequencing is very difficult. Recently, targeted exome sequencing has been developed and applied as a diagnostic tool for epileptic disorders. 33 Targeted exome sequencing as well as WES would be quite useful for genetic testing for EOEEs.
